MediciNova. has been granted a patent for a method to prevent cancer metastasis by administering ibudilast or its pharmaceutical salts. This approach targets various cancers, including pancreatic, lung, breast, colorectal, melanoma, and ovarian cancers, aiming to minimize disease progression in affected patients. GlobalData’s report on MediciNova gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MediciNova, Peptide pharmacophores was a key innovation area identified from patents. MediciNova's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (US12042485B2) outlines a method for reducing or preventing cancer metastasis in patients, specifically targeting various types of cancer, including pancreatic, lung, breast, colorectal, melanoma, and ovarian cancers. The method involves administering ibudilast, or its pharmaceutically acceptable salts, in therapeutically effective amounts. The claims detail that ibudilast can be used alone or in combination with other active agents, such as chemotherapy, immunotherapy, and epigenetic therapies, as well as various surgical and radiological interventions. The administration of ibudilast can be tailored to the patient's needs, with suggested durations ranging from three months to two years, and dosages varying from 0.1 mg to 720 mg per day.
The patent further specifies that ibudilast can be given as adjuvant therapy and may be administered orally or in divided doses. The claims also provide a comprehensive list of potential additional agents that can be combined with ibudilast, including well-known chemotherapy drugs and immunotherapeutic agents. This patent represents a significant advancement in cancer treatment methodologies, offering a potential new avenue for managing metastasis in patients suffering from various malignancies.
To know more about GlobalData’s detailed insights on MediciNova, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
